 Nicole Massoll
Concepts (210)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Nodule | 5 | 2022 | 32 | 1.080 |
Why?
| | Thyroid Neoplasms | 8 | 2022 | 113 | 1.050 |
Why?
| | Biopsy, Fine-Needle | 7 | 2024 | 104 | 0.570 |
Why?
| | Uterus | 2 | 2008 | 81 | 0.490 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 62 | 0.490 |
Why?
| | Papillomavirus Infections | 2 | 2008 | 177 | 0.430 |
Why?
| | Carcinoma, Papillary | 3 | 2017 | 50 | 0.430 |
Why?
| | Breast Neoplasms | 6 | 2018 | 1222 | 0.360 |
Why?
| | Vulvar Neoplasms | 3 | 2008 | 61 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2008 | 332 | 0.330 |
Why?
| | Cysts | 2 | 2006 | 53 | 0.300 |
Why?
| | MicroRNAs | 3 | 2022 | 397 | 0.300 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2008 | 301 | 0.270 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2008 | 51 | 0.270 |
Why?
| | Precancerous Conditions | 1 | 2008 | 87 | 0.270 |
Why?
| | Carcinoma, Lobular | 1 | 2007 | 32 | 0.260 |
Why?
| | Cytological Techniques | 1 | 2006 | 13 | 0.250 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2007 | 89 | 0.240 |
Why?
| | Adenomyoma | 1 | 2005 | 2 | 0.230 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2005 | 8 | 0.230 |
Why?
| | Carcinoma in Situ | 2 | 2008 | 72 | 0.230 |
Why?
| | Biopsy, Needle | 1 | 2006 | 181 | 0.230 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2005 | 29 | 0.230 |
Why?
| | Lymph Nodes | 3 | 2017 | 252 | 0.230 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 3 | 2010 | 17 | 0.230 |
Why?
| | Uterine Neoplasms | 1 | 2005 | 57 | 0.230 |
Why?
| | Competency-Based Education | 1 | 2024 | 31 | 0.220 |
Why?
| | Carcinoma, Medullary | 1 | 2004 | 12 | 0.210 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 124 | 0.200 |
Why?
| | Mastectomy | 2 | 2018 | 147 | 0.190 |
Why?
| | Humans | 31 | 2024 | 53230 | 0.190 |
Why?
| | Clinical Competence | 1 | 2024 | 406 | 0.180 |
Why?
| | Pathology | 3 | 2024 | 37 | 0.170 |
Why?
| | Focal Adhesion Kinase 1 | 2 | 2012 | 14 | 0.170 |
Why?
| | Diagnosis, Differential | 4 | 2008 | 1038 | 0.160 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 31 | 0.160 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2020 | 27 | 0.160 |
Why?
| | Female | 20 | 2020 | 28782 | 0.160 |
Why?
| | Mutation | 6 | 2022 | 1337 | 0.160 |
Why?
| | DNA, Neoplasm | 2 | 2018 | 146 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2015 | 645 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 78 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2012 | 233 | 0.150 |
Why?
| | Immunohistochemistry | 6 | 2015 | 975 | 0.140 |
Why?
| | Thyroid Gland | 3 | 2020 | 76 | 0.130 |
Why?
| | Pancreatic Neoplasms | 2 | 2010 | 219 | 0.130 |
Why?
| | Gene Silencing | 2 | 2008 | 122 | 0.130 |
Why?
| | Neoplasm Invasiveness | 5 | 2015 | 281 | 0.120 |
Why?
| | Middle Aged | 10 | 2020 | 13419 | 0.120 |
Why?
| | DNA, Viral | 2 | 2008 | 136 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2016 | 55 | 0.120 |
Why?
| | Pulmonary Medicine | 1 | 2015 | 15 | 0.120 |
Why?
| | Fibroblasts | 2 | 2016 | 363 | 0.120 |
Why?
| | Cytodiagnosis | 1 | 2015 | 42 | 0.120 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 867 | 0.110 |
Why?
| | Cell Proliferation | 4 | 2016 | 1031 | 0.110 |
Why?
| | Endosonography | 1 | 2015 | 98 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2017 | 211 | 0.110 |
Why?
| | Adult | 9 | 2020 | 14534 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3494 | 0.100 |
Why?
| | Receptor, erbB-2 | 2 | 2018 | 79 | 0.100 |
Why?
| | Laryngeal Diseases | 1 | 2013 | 12 | 0.100 |
Why?
| | Laryngectomy | 1 | 2013 | 27 | 0.100 |
Why?
| | Herpes Simplex | 1 | 2013 | 25 | 0.100 |
Why?
| | Purine Nucleosides | 1 | 2012 | 3 | 0.100 |
Why?
| | Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.090 |
Why?
| | Immunoenzyme Techniques | 2 | 2008 | 134 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 934 | 0.080 |
Why?
| | Receptors, Somatomedin | 1 | 2010 | 8 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 8 | 0.080 |
Why?
| | Tissue Fixation | 2 | 2020 | 35 | 0.080 |
Why?
| | Melanoma | 1 | 2012 | 277 | 0.080 |
Why?
| | Aniline Compounds | 1 | 2009 | 48 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2022 | 6819 | 0.070 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2008 | 3 | 0.070 |
Why?
| | Cell Movement | 1 | 2009 | 279 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2008 | 55 | 0.070 |
Why?
| | Transglutaminases | 1 | 2008 | 14 | 0.070 |
Why?
| | Biopsy | 2 | 2007 | 600 | 0.070 |
Why?
| | Mastitis | 1 | 2007 | 3 | 0.070 |
Why?
| | Aged | 5 | 2020 | 10429 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 104 | 0.070 |
Why?
| | GTP-Binding Proteins | 1 | 2008 | 85 | 0.070 |
Why?
| | Genes, erbB-2 | 1 | 2007 | 8 | 0.070 |
Why?
| | Prednisone | 1 | 2007 | 101 | 0.060 |
Why?
| | Granuloma | 1 | 2007 | 46 | 0.060 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2008 | 180 | 0.060 |
Why?
| | Group Practice | 1 | 2006 | 3 | 0.060 |
Why?
| | Cystatins | 1 | 2006 | 1 | 0.060 |
Why?
| | Cadherins | 1 | 2007 | 62 | 0.060 |
Why?
| | Frozen Sections | 1 | 2006 | 13 | 0.060 |
Why?
| | Genomic Instability | 1 | 2007 | 88 | 0.060 |
Why?
| | Specialization | 1 | 2006 | 48 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 162 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 579 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 228 | 0.060 |
Why?
| | Medicine | 1 | 2006 | 51 | 0.060 |
Why?
| | RNA, Small Interfering | 3 | 2012 | 214 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 465 | 0.060 |
Why?
| | Gene Expression | 1 | 2008 | 618 | 0.060 |
Why?
| | Antigens, CD | 1 | 2007 | 217 | 0.060 |
Why?
| | Mullerian Ducts | 1 | 2005 | 4 | 0.060 |
Why?
| | Medical Oncology | 1 | 2006 | 97 | 0.060 |
Why?
| | Fallopian Tubes | 1 | 2005 | 22 | 0.060 |
Why?
| | Estrogen Replacement Therapy | 1 | 2005 | 28 | 0.060 |
Why?
| | Chromosome Aberrations | 1 | 2007 | 297 | 0.060 |
Why?
| | Signal Transduction | 1 | 2012 | 1748 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2007 | 236 | 0.060 |
Why?
| | Data Collection | 1 | 2006 | 288 | 0.060 |
Why?
| | ABO Blood-Group System | 1 | 2005 | 16 | 0.060 |
Why?
| | Vulva | 1 | 2005 | 18 | 0.060 |
Why?
| | Ovariectomy | 1 | 2005 | 114 | 0.060 |
Why?
| | Hysterectomy | 1 | 2005 | 91 | 0.060 |
Why?
| | Mice, Nude | 3 | 2010 | 232 | 0.060 |
Why?
| | Regression Analysis | 1 | 2006 | 391 | 0.060 |
Why?
| | Decision Making | 1 | 2007 | 278 | 0.060 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2005 | 54 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2006 | 218 | 0.060 |
Why?
| | Papillomaviridae | 1 | 2005 | 104 | 0.050 |
Why?
| | Cell Survival | 3 | 2012 | 600 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 412 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2009 | 1470 | 0.050 |
Why?
| | Mice | 5 | 2017 | 5982 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 1557 | 0.050 |
Why?
| | Ultrasonography | 1 | 2006 | 426 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 452 | 0.050 |
Why?
| | Male | 6 | 2020 | 27435 | 0.050 |
Why?
| | Base Sequence | 3 | 2010 | 620 | 0.050 |
Why?
| | Prospective Studies | 2 | 2022 | 2411 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 219 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2007 | 1112 | 0.040 |
Why?
| | Formaldehyde | 1 | 2020 | 51 | 0.040 |
Why?
| | Oncogenes | 1 | 2020 | 61 | 0.040 |
Why?
| | Adolescent | 2 | 2015 | 6907 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2015 | 774 | 0.040 |
Why?
| | Transplantation, Heterologous | 2 | 2010 | 78 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 1232 | 0.040 |
Why?
| | Animals | 5 | 2017 | 13526 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 587 | 0.040 |
Why?
| | DNA Primers | 2 | 2010 | 202 | 0.040 |
Why?
| | Paraffin Embedding | 1 | 2018 | 52 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 4511 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2018 | 68 | 0.030 |
Why?
| | Specimen Handling | 1 | 2018 | 63 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 134 | 0.030 |
Why?
| | Methylene Blue | 1 | 2017 | 7 | 0.030 |
Why?
| | Lymphatic System | 1 | 2017 | 13 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 54 | 0.030 |
Why?
| | Coloring Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2017 | 163 | 0.030 |
Why?
| | Prognosis | 2 | 2015 | 2118 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2015 | 2318 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2006 | 5595 | 0.030 |
Why?
| | Apoptosis | 2 | 2012 | 1139 | 0.030 |
Why?
| | Cost Savings | 1 | 2015 | 60 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 128 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2008 | 1133 | 0.030 |
Why?
| | Collagen | 1 | 2016 | 215 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 274 | 0.030 |
Why?
| | Disease Progression | 2 | 2008 | 880 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 274 | 0.030 |
Why?
| | DNA Methylation | 2 | 2008 | 592 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 56 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2012 | 54 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 400 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 1016 | 0.020 |
Why?
| | Staurosporine | 1 | 2009 | 10 | 0.020 |
Why?
| | Deoxycytidine | 1 | 2009 | 26 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 147 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2009 | 163 | 0.020 |
Why?
| | RNA Interference | 1 | 2009 | 181 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2009 | 228 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2008 | 18 | 0.020 |
Why?
| | Luciferases | 1 | 2008 | 50 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2008 | 48 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 46 | 0.020 |
Why?
| | Florida | 1 | 2008 | 70 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 68 | 0.020 |
Why?
| | Fluorouracil | 1 | 2008 | 59 | 0.020 |
Why?
| | Loss of Heterozygosity | 1 | 2008 | 78 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 533 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 93 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2008 | 128 | 0.020 |
Why?
| | Estrogens | 1 | 2009 | 224 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2008 | 136 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 359 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 371 | 0.020 |
Why?
| | Ultrasonography, Mammary | 1 | 2007 | 61 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2008 | 487 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 759 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2008 | 374 | 0.020 |
Why?
| | Cystatin M | 1 | 2006 | 17 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 29 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 45 | 0.020 |
Why?
| | Cesarean Section | 1 | 2007 | 158 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 949 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2008 | 910 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 868 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 1569 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2005 | 291 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2008 | 647 | 0.010 |
Why?
| | Pregnancy Complications | 1 | 2007 | 406 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 1180 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 2913 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 1583 | 0.010 |
Why?
| | Pregnancy | 1 | 2007 | 2608 | 0.010 |
Why?
| | Infant | 1 | 2008 | 3805 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 4162 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 4017 | 0.010 |
Why?
| | Child | 1 | 2008 | 7379 | 0.010 |
Why?
|
|
Massoll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|